Min SY, Kim HS, Jung EJ, Jung EJ, Jee CD, Kim WH
ResMed CEO: Big Pharma is squarely focused on GLP-1 medications right now Image courtesy of ResMed ResMed CEO Mick Farrells stance on the issue is that the latest advances in both Big Tech and Big Pharma can potentially bring incredible numbers of new patients into the healthcare system where ResMed is uniquely positioned to provide ongoing care at home. Patients are voting with their wallets and respiratory therapists and physicians are voting with their recommendations and their prescriptions. During the companys first-quarter earnings call, Farrell said the company is laser-focused on growing the market to help people get on the therapy they need and on a pathway to better sleep, better health, and better long-term care
But when it
Purpose-built for physicians GLP-1 does not slow Parkinsons disease progression in phase 3 study Key takeaways: Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinsons disease
Por ello, si est embarazada o en periodo de lactancia, se recomienda hablar de ello con su mdico de cabecera antes de iniciar cualquier tratamiento
At first, Eng tried to point this remarkable feature of Gila monster spit out to pharmaceutical makers and the government